We are live on ! Find out more
CNTB

Connect Biopharma Holdings
CNTB

16 hedge funds and large institutions have $10.9M invested in Connect Biopharma Holdings in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more capital invested

Capital invested by funds: $9.6M → $10.9M (+$1.32M)

0.27% less ownership

Funds ownership: 20.1% → 19.83% (-0.27%)

20% less funds holding

Funds holding: 20 → 16 (-4)

67% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 6

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
16
Holders Change
-4
Holders Change %
-20%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
6
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UOC
UBS O'Connor
Illinois
+$626K
2
JP Morgan Chase
JP Morgan Chase
New York
+$79.6K
3
Renaissance Technologies
Renaissance Technologies
New York
+$5.67K

Top Sellers

Rank Fund Capital Flow
1
SCM
Sio Capital Management
New York
-$519K
2
Citigroup
Citigroup
New York
-$121K
3
E
Ergoteles
New York
-$38.4K
4
UBS Group
UBS Group
Switzerland
-$9.6K
5
TRCT
Tower Research Capital (TRC)
New York
-$9K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$6.99M – – –
BlackRock
2
BlackRock
New York
$1.13M – – –
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$1.03M – – –
KCM
4
Kynam Capital Management
New Jersey
$740K – – –
UOC
5
UBS O'Connor
Illinois
$574K +$626K +574,148 New
IC
6
Ikarian Capital
Texas
$219K – – –
Renaissance Technologies
7
Renaissance Technologies
New York
$89K +$5.67K +5,200 +6%
JP Morgan Chase
8
JP Morgan Chase
New York
$79K +$79.6K +72,987 +1,313%
BFM
9
Boothbay Fund Management
New York
$26.9K – – –
Susquehanna International Group
10
Susquehanna International Group
Pennsylvania
$20.7K -$289 -265 -1%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$19K – – –
UBS Group
12
UBS Group
Switzerland
$9.34K -$9.6K -8,798 -49%
Fidelity Investments
13
Fidelity Investments
Massachusetts
$33 -$55 -50 -60%
Bank of America
14
Bank of America
North Carolina
$2 -$11 -10 -83%
Morgan Stanley
15
Morgan Stanley
New York
$1 -$390 -358 -100%
SCM
16
Sio Capital Management
New York
– -$519K -597,678 Closed
Citigroup
17
Citigroup
New York
– -$121K -139,196 Closed
E
18
Ergoteles
New York
– -$38.4K -44,297 Closed
TRCT
19
Tower Research Capital (TRC)
New York
– -$9K -10,398 Closed
Royal Bank of Canada
20
Royal Bank of Canada
Ontario, Canada
– -$43 -39 -49%

CNTB Hedge Fund Activity: Q1 2023 in Review

16 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Connect Biopharma Holdings (CNTB) for Q1 2023, worth a combined $10.9M — up 14% from $9.6M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of CNTB and 1 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 2 added.

The largest buyer was UBS O'Connor, opening a new position worth an estimated $626K. The largest seller was Sio Capital Management, exiting entirely with an estimated $519K sold.

  • 16 institutional investors held Connect Biopharma Holdings (CNTB) as of Q1 2023, down from 20 in Q4 2022.
  • Funds reported $10.9M of Connect Biopharma Holdings stock for Q1 2023, up 14% quarter-over-quarter.
  • 1 fund opened new Connect Biopharma Holdings positions in Q1 2023 and 5 closed out, a net change of -4 holders.
  • The largest Connect Biopharma Holdings buyer in Q1 2023 was UBS O'Connor, an estimated $626K added.
  • The largest Connect Biopharma Holdings seller in Q1 2023 was Sio Capital Management, an estimated $519K sold.

Based on aggregated 13F filings for Q1 2023.